Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Trifluoperazine: A Sprightly Old Drug.
Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism.
Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care.
'Non-criteria' neurologic manifestations of antiphospholipid syndrome: A hidden kingdom to be discovered.
Differential Regulation of Self-reactive CD4(+) T Cells in Cervical Lymph Nodes and Central Nervous System during Viral Encephalomyelitis.
Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS - NO.
Comparison of myelin water fraction values in periventricular white matter lesions between MS and NMOSD.
Down-regulation of neuronal L1 cell adhesion molecule expression alleviates inflammatory neuronal injury.
HIV-1 Tat Inhibits Autotaxin Lysophospholipase D Activity and Modulates Oligodendrocyte Differentiation.
Benefits from an autobiographical memory facilitation programme in relapsing-remitting multiple sclerosis patients: a clinical and neuroimaging study.
Rituximab for treating multiple sclerosis: Off-label but on target.
Comparison of serum Concentration of Se, Pb, Mg, Cu, Zn, between MS patients and healthy controls.
Characterizing axonal myelination within the healthy population: a tract-by-tract mapping of effects of age and gender on the fiber g-ratio.
Type 1 diabetes and susceptibility to multiple sclerosis: What is the truth?
Patient Management Problem.
Population PK-PD Analyses of CD25 Occupancy, CD56(bright) NK Cell Expansion, and Regulatory T Cell Reduction by Daclizumab HYP in Subjects with Multiple Sclerosis.
Lack of correlation between extracranial venous abnormalities and multiple sclerosis: a quantitative MRI study.
Quantification of Gait Abnormalities in Healthy-Looking Multiple Sclerosis Patients (with Expanded Disability Status Scale 0-1.5).
Recovery from Toxic-Induced Demyelination Does Not Require the NG2 Proteoglycan.
The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis.
The value of histopathological diagnosis in the elderly patients with granulomatous dermatoses. Case series.
The Adaptor Protein Rai/ShcC Promotes Astrocyte-Dependent Inflammation during Experimental Autoimmune Encephalomyelitis.
Global progress in the control of viral hepatitis and acceptable delay in Hepatitis B immunization.
Epilepsy in multiple sclerosis: The role of temporal lobe damage.
The emerging role of the cannabinoid receptor family in peripheral and neuro-immune interactions.
Pages
« first
‹ previous
…
801
802
803
804
805
806
807
808
809
…
next ›
last »